Interdisciplinary

Unique Environment

Precision Oncology

Molecular Mechanisms

Innovation

Translation and Reverse Translation

Spirit of collaboration

Exceptional Career Opportunities

Interdisciplinary Education

Team Culture

Bottom-up Ideas

Shared Cutting Edge Resources

Research at FCI

Clinical Translation Programs
Strategic Core of FCI

Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided by the five research areas.

Read more

R1
Molecular Diagnostic and Biomarker

The goal of Research Area 1 is to find individual parameters that can improve the diagnosis of tumors or better predict the response to therapy. For example, the composition of all proteins in a cell can be qualitatively and quantitatively analyzed by means of mass spectrometry.

Read more

R2
Molecular Mechanisms of Tumor Pathogenesis

Elucidating the underlying causes of the individually different treatment responses in order to develop new therapeutic or diagnostic concepts based on the findings, is a fundamental goal of Research Area 2. To achieve this goal, it is essential to understand the molecular mechanisms that drive tumor development and progression. Research Area 2 combines the expertise in structural biology, biochemistry and cell biology within the FCI to analyze the tumorigenesis, the response to therapy and resistance mechanisms systematically and functionally in the overall cellular context at the molecular level. In line with the interdisciplinarity of the FCI, the molecular-pathophysiological mechanisms that underlie the clinical observations are elaborated on the basis of individual tumor samples.

Read more

R3
Preclinical Models

This area is the essential link transferring new therapeutic strategies to the clinic. Far too often, promising substances fail in later clinical development. The lack of meaningful preclinical models is an important reason for this low success rate. The aim of Research Area 3 is therefore to develop new models enhancing the clinical success of a drug identified in basic research by better predicting the response in patients.

Read more

R4
Drug Development and Novel Therapeutic Approaches

The goal of Research Area 4 is to develop new therapeutic approaches and to advance them to the development of new drugs. The extensive chemical, pharmaceutical and structural biology expertise at the Goethe University in Frankfurt enables the development and optimization of new drug candidates against validated target structures. At the Georg-Speyer-Haus and at the Paul Ehrlich Institute, innovative "biologicals" and cell therapeutics are being developed for which there are certified production areas at the Institute of Transfusion Medicine.

Read more

R5
Clinical Trials

The integration of clinical trials into FCI is essential both as an end point of drug development and as a starting point for research on response and resistance mechanisms. The aim is to initiate such studies in close cooperation with the University Cancer Center (UCT). UCT Frankfurt has been continuously working on the development of a comprehensive clinical research unit, which will be fully available to the FCI. The practical implementation of early translational studies at the FCI site is guaranteed.

Read more

Discovery & Development

The primary objective of this program is to address excellent hypotheses on basic biological mechanisms of tumorigenesis, progression, diagnosis, and therapy.

Read more

Events

Paul Ehrlich and Ludwig Darmstaedter Early Career Award 2023

15-09-2022
12:00
Various, Various
PAUL EHRLICH FOUNDATION
Lecture Hall Georg-Speyer-Haus
mehr erfahren
Save Event

Engineering Lymphocytes for the Immunotherapy of Pediatric Cancer

16-09-2022
15:00
Stephen Gottschalk, Department of BMT & Cellular Therapy St. Jude Children’s Research Hospital Memphis, TN
Jan-Henning Klusmann; Evelyn Ullrich, Winfried Wels
Building 32C, Room B15 & virtuell
Save Event

The mechanics of NK cell cytotoxicity and opportunities to improve cellular therapies for cancer

09-11-2022
15:30
Jordan Orange, Columbia University & Morgan Stanley Children’s Hospital
Winfried Wels
Lecture Hall Georg-Speyer-Haus
Save Event

Press Releases

2022-07-20

A new Clinician Scientist Programm INDEEP led by Evelyn Ullrich receives millions to provide time for research

To the article

2022-03-04

New leukemia subgroup identified for the first time solely by altered proteome

To the article

2022-02-04

New resistance mechanism in rectal cancer therapy discovered: inflammatory connective tissue cells reduce response to radiochemotherapy

To the article